Endpoints News
UK’s NICE revisits Lilly, Eisai Alzheimer’s drugs under new pricing threshold
The UK’s drug watchdog is reconsidering two Alzheimer’s disease medicines after rejecting them for being too expensive.
The National Institute for Health and Care Excellence last year determined that Eli Lilly’s donanemab, marketed as Kisunla …